albuterol has been researched along with Myocardial Ischemia in 4 studies
Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Albuterol is known to induce myocardial ischemia." | 7.73 | Albuterol-induced myocardial ischemia in sickle cell anemia after hemolysis from ceftriaxone administration. ( Corso, M; Ravindranath, TM, 2005) |
| " The first, consisting of patients transported for respiratory distress having received at least 10 mg of albuterol, was studied for development of tachycardia and hypotension." | 3.79 | Diastolic hypotension is an unrecognized risk factor for β-agonist-associated myocardial injury in children with asthma. ( Arora, G; Felmet, KA; Kuch, BA; Manole, M; Orr, RA; Pitetti, RA; Saladino, RA; Sarnaik, SM, 2013) |
| " Albuterol is known to induce myocardial ischemia." | 3.73 | Albuterol-induced myocardial ischemia in sickle cell anemia after hemolysis from ceftriaxone administration. ( Corso, M; Ravindranath, TM, 2005) |
| " The frequency of adverse events, COPD exacerbations, and use of short-acting bronchodilator agents were assessed throughout the study period." | 2.73 | Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. ( Baumgartner, RA; Donohue, JF; Goodwin, E; Grogan, DR; Hanania, NA; Hanrahan, JP; Sciarappa, KA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarnaik, SM | 1 |
| Saladino, RA | 1 |
| Manole, M | 1 |
| Pitetti, RA | 1 |
| Arora, G | 1 |
| Kuch, BA | 1 |
| Orr, RA | 1 |
| Felmet, KA | 1 |
| Donohue, JF | 1 |
| Hanania, NA | 1 |
| Sciarappa, KA | 1 |
| Goodwin, E | 1 |
| Grogan, DR | 1 |
| Baumgartner, RA | 1 |
| Hanrahan, JP | 1 |
| Corso, M | 1 |
| Ravindranath, TM | 1 |
| Martin, RM | 1 |
| Dunn, NR | 1 |
| Freemantle, SN | 1 |
| Mann, RD | 1 |
1 trial available for albuterol and Myocardial Ischemia
| Article | Year |
|---|---|
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
Topics: Albuterol; Arrhythmias, Cardiac; Bronchitis; Bronchodilator Agents; Ethanolamines; Female; Forced Ex | 2008 |
3 other studies available for albuterol and Myocardial Ischemia
| Article | Year |
|---|---|
Diastolic hypotension is an unrecognized risk factor for β-agonist-associated myocardial injury in children with asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Biomarkers; Child; Child, Preschool; Cohort Studies; | 2013 |
Albuterol-induced myocardial ischemia in sickle cell anemia after hemolysis from ceftriaxone administration.
Topics: Adrenergic beta-Agonists; Albuterol; Anemia, Hemolytic; Anemia, Sickle Cell; Ceftriaxone; Child; Hum | 2005 |
Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists.
Topics: Adrenergic beta-Agonists; Adult; Adverse Drug Reaction Reporting Systems; Aged; Albuterol; Anti-Asth | 1998 |